弥漫大 B 细胞淋巴瘤患者中 tisagenlecleucel 和 axicabtagene ciloleucel 相关的真实世界医疗资源利用与成本：美国医院数据分析

This study compared the real-world healthcare resource utilization (HRU), costs, adverse events (AEs), and AE treatments associated with the chimeric antigen receptor T-cell (CAR-T) therapies, tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel), for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Adults with DLBCL who received tisa-cel or axi-cel were identified in the Premier Healthcare Database (2017-2020). Non-CAR-T costs, HRU, and AE rates during the infusion and follow-up periods were compared between the tisa-cel and axi-cel cohorts.

Of 119 patients, 33 received tisa-cel (86% as inpatient infusion) and 86 received axi-cel (100% inpatient). Tisa-cel was associated with significantly shorter mean inpatient length of stay than axi-cel during infusion (11. 3 vs. 18. 3 days) and follow-up ([monthly] 3. 9 vs. 6. 9 days). Non-CAR-T costs were significantly lower for tisa-cel compared with axi-cel during infusion ($27594. 8 vs. $51378. 3) and follow-up ([monthly] $28777. 3 vs. $46575. 7; both p < . 05). Rates of AEs and AE treatments were similar.